文献速递术前评估与围术期医学气道管理

肌松拮抗剂选择与术后肺部并发症风险的匹配队列研究

Association between choice of reversal agent for neuromuscular block and postoperative pulmonary complications in patients at increased risk undergoing non-emergency surgery: STIL-STRONGER, a multicentre matched cohort study.
PubMed 文献 · Br J Anaesth · 2022-06-09

本研究为STRONGER研究的二次分析,采用多中心回顾性匹配队列设计,纳入3817对术后肺部并发症风险升高的非急诊手术患者。结果显示,与新斯的明相比,舒更葡糖拮抗与肺炎或呼吸衰竭复合结局风险降低独立相关(5.9% vs 2.6%,OR 0.41,校正OR 0.39)。

要点

  • 高风险患者使用舒更葡糖拮抗肌松,术后肺炎或呼吸衰竭风险低于新斯的明。
  • 匹配后主要结局发生率:新斯的明组5.9%,舒更葡糖组2.6%。
  • 该关联为观察性结果,需结合临床情境个体化选择拮抗剂。

核心结论

  • 在术后肺部并发症风险升高的患者中,与新斯的明相比,使用舒更葡糖拮抗神经肌肉阻滞与后续肺炎或呼吸衰竭风险降低独立相关。

研究设计与样本

  • 多中心回顾性匹配队列研究,为STRONGER研究的二次分析,数据来自多中心围术期结局组。
  • 纳入18岁及以上、全麻气管插管并使用肌松药及拮抗剂的非急诊手术患者,预测术后肺部并发症风险升高。
  • 风险升高定义为ASA体能状态3或4级,接受胸腔内或腹腔内手术,且年龄>80岁或手术时长>2小时。
  • 按机构、性别、年龄(±5岁)、BMI、手术解剖区域、合并症及肌松药匹配后,保留3817对匹配病例。

主要发现

  • 主要复合结局(肺炎或呼吸衰竭)在新斯的明组发生224例,舒更葡糖组100例(5.9% vs 2.6%,OR 0.41,P<0.01)。
  • 校正不平衡协变量后,舒更葡糖使用与主要结局的校正OR为0.39(P<0.0001)。

临床怎么用

  • 对于术后肺部并发症风险升高的非急诊手术患者,选择舒更葡糖而非新斯的明拮抗肌松可能与降低肺炎或呼吸衰竭风险相关。

局限性

  • 本研究为回顾性匹配队列研究,存在残余混杂可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative pulmonary complications are a source of morbidity after major surgery. In patients at increased risk of postoperative pulmonary complications we sought to assess the association between neuromuscular blocking agent reversal agent and development of postoperative pulmonary complications. METHODS: We conducted a retrospective matched cohort study, a secondary analysis of data collected in the prior STRONGER study. Data were obtained from the Multicenter Perioperative Outcomes Group. Included patients were aged 18 yr and older undergoing non-emergency surgery under general anaesthesia with tracheal intubation with neuromuscular block and reversal, who were predicted to be at elevated risk of postoperative pulmonary complications. This risk was defined as American Society of Anesthesiologists Physical Status 3 or 4 in patients undergoing either intrathoracic or intra-abdominal surgery who were either aged >80 yr or underwent a procedure lasting >2 h. Cohorts were defined by reversal with neostigmine or sugammadex. The primary composite outcome was the occurrence of pneumonia or respiratory failure. RESULTS: After matching by institution, sex, age (within 5 yr), body mass index, anatomic region of surgery, comorbidities, and neuromuscular blocking agent, 3817 matched pairs remained. The primary postoperative pulmonary complications outcome occurred in 224 neostigmine cases vs 100 sugammadex cases (5.9% vs 2.6%, odds ratio 0.41, P<0.01). After adjustment for unbalanced covariates, the adjusted odds ratio for the association between sugammadex use and the primary outcome was 0.39 (P<0.0001). CONCLUSIONS: In a cohort of patients at increased risk for pulmonary complications compared with neostigmine, use of sugammadex was independently associated with reduced risk of subsequent development of pneumonia or respiratory failure.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Colquhoun DA, Vaughn MT, Bash LD, et al. Association between choice of reversal agent for neuromuscular block and postoperative pulmonary complications in patients at increased risk undergoing non-emergency surgery: STIL-STRONGER, a multicentre matched cohort study. Br J Anaesth. 2022. PMID: 35691703. doi:10.1016/j.bja.2022.04.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。